Short answer
Monopar Therapeutics (MNPR) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.
Monopar Therapeutics 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release furnished as Exhibit 99.1, containing the company’s reported results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 net loss widened to $6.2M, or $0.72 per share, from $3.4M, or $0.48 per share
- Cash, equivalents and investments totaled $129.4M, supporting operations through at least March 31, 2028
- NDA submission for ALXN1840 remains on track for completion within the next several weeks
- Phase 3 findings showed residual disease burden despite treatment, supporting potential unmet need in Wilson disease
- R&D expenses rose to $4.44M from $2.59M, reflecting higher contractors, consulting and personnel costs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Monopar Therapeutics 8-K filings
Get the next MNPR 8-K as it lands
Follow MNPR for push alerts, or ask the research agent what this filing means.